EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from …
WEBOct 5, 2023 · EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA. First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years. TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron ...
FDA approves first interchangeable biosimilars to Eylea to treat ...
WEBMay 20, 2024 · FDA approved Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept). Aflibercept products work by inhibiting …
Regeneron fends off Viatris' Eylea biosimilar with patent win
WEBDec 29, 2023 · A West Virginia judge ruled that Viatris' proposed biosimilar violates a Regeneron patent that covers ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein...
US FDA approves two biosimilars for blockbuster eye drug Eylea
WEBMay 20, 2024 · The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the blockbuster eye...
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for …
WEBEYLEA HD (aflibercept) 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema …
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA …
WEBOct 21, 2022 · EYLEA ® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein ...
US FDA declines to approve Regeneron's higher-dose Eylea, …
WEBJun 28, 2023 · U.S. health regulators on Tuesday declined to approve a higher-dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is leading cause of blindness among the...
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from …
WEBTARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal...
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age …
WEBMar 8, 2024 · EYLEA HD has shown impressive durable visual improvements and rapid and resilient fluid control with a safety profile comparable to EYLEA. Extended dosing intervals with EYLEA HD have the potential to substantially reduce treatment burden for patients. EYLEA HD has been approved in multiple countries including the …
Eylea™ 8 mg data presentations at ARVO reinforce sustained and ...
WEBBerlin, April 29, 2024 – Bayer announced today that new long-term results and subgroup analyses from the pivotal clinical trial program of aflibercept 8 mg (Eylea™ 8 mg) in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) will be presented at the Annual Meeting of …